{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:03:50Z","timestamp":1792181030599,"version":"4.4.0"},"reference-count":27,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cisplatin-associated acute kidney injury (C-AKI) is common. Predictive factors include age &gt;60 years, hypertension, cisplatin dose, diabetes, and serum albumin\u2009&lt;\u20093.5 g\/L. The association between C-AKI and hypokalemia, hypomagnesemia or hyponatremia has not been well characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data from a previous retrospective observational study was obtained. Patients were separated into three groups with similar cisplatin doses and schedules. Group A received cisplatin 60\u2013100 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      every three weeks with laboratory assessments before treatment, group B received cisplatin 60\u201375 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      every three weeks with laboratory assessments before days 1 and 8 and group C had weekly cisplatin 40 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      with weekly laboratories assessments. The association between hypomagnesemia, hypokalemia, hyponatremia, and risk of AKI was determined using a counting process specification of Cox's regression models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1301 patients were separated into groups A (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009713), B (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009204), and C (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009384). The proportion of patients with at least one event of hypokalemia, hypomagnesemia, or hyponatremia was lower in group A (29.2%, 57.6%, 36.2%) compared to groups B (43.6%, 67.2%, 59.8%) and C (49.0%, 78.7%, 51.0%). The incidence of all grade C-AKI was 35.6% (group A), 46.6% (group B), and 18.2% (group C). In group A, the risk of AKI doubled with hyponatremia or hypomagnesemia and tripled with hypokalemia. This association was not seen with other groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among patients with the highest doses of cisplatin, the presence of one electrolyte disorder was associated with an increased risk of C-AKI. Other studies are needed to characterize the presence of an electrolyte disorder as a predictive risk factor of C-AKI in this subpopulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241262248","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T07:48:33Z","timestamp":1721893713000},"page":"754-760","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Hypokalemia, hypomagnesemia, and hyponatremia are associated with acute kidney injury in patients treated with cisplatin"],"prefix":"10.1177","volume":"31","author":[{"given":"Louis","family":"Pinard","sequence":"first","affiliation":[{"name":"Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7938-0944","authenticated-orcid":false,"given":"Jean-Philippe","family":"Adam","sequence":"additional","affiliation":[{"name":"Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Chagnon","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montr\u00e9al"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Boll\u00e9e","sequence":"additional","affiliation":[{"name":"Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Souli\u00e8res","sequence":"additional","affiliation":[{"name":"Axe cancer, Centre de recherche du Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM), Montr\u00e9al, QC, Canada"},{"name":"Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000339789"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31812dfe1e"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3392-8"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins2112490"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002786"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1691"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/10408444.2011.602662"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00127.2014"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.644"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu004"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100351"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01182-1"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05703-7"},{"key":"e_1_3_2_15_2","unstructured":"US Department of Health and Human Services National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5 ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50 (2017 accessed 14 November 2022)."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.7161"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000510384"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy133"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-019-00617-y"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-009-0215-1"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-7-10"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0400"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(85)90033-1"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00779"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.03.004"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-018-0615-y"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23536"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0319"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241262248","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241262248","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241262248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:58Z","timestamp":1777688998000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241262248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/10781552241262248"],"URL":"https:\/\/doi.org\/10.1177\/10781552241262248","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]}}}